These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37015029)

  • 21. Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases.
    Li J; Chen T; Bi F; Yang Y
    Tumori; 2021 Dec; 107(6):NP114-NP119. PubMed ID: 34296632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps.
    Rizzo A; Palmiotti G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):331. PubMed ID: 35196947
    [No Abstract]   [Full Text] [Related]  

  • 23. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.
    Xu G; Cui L; Li J; Wang Q; Li P; Xia X; Yi X; Guan Q; Xu J
    Clin Transl Med; 2022 Oct; 12(10):e1086. PubMed ID: 36245284
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
    Scheiner B; Kirstein MM; Hucke F; Finkelmeier F; Schulze K; von Felden J; Koch S; Schwabl P; Hinrichs JB; Waneck F; Waidmann O; Reiberger T; Müller C; Sieghart W; Trauner M; Weinmann A; Wege H; Trojan J; Peck-Radosavljevic M; Vogel A; Pinter M
    Aliment Pharmacol Ther; 2019 May; 49(10):1323-1333. PubMed ID: 30980420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
    Campion B; Larrey E; Wagner M; Rudler M; Thabut D; Allaire M
    Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101785. PubMed ID: 34384926
    [No Abstract]   [Full Text] [Related]  

  • 28. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
    Turkes F; Chau I
    Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of de novo psoriasis secondary to atezolizumab in a patient with hepatocellular carcinoma.
    Lim JH; Lo Y
    Kaohsiung J Med Sci; 2022 Nov; 38(11):1135-1136. PubMed ID: 36177804
    [No Abstract]   [Full Text] [Related]  

  • 30. Phototoxic drug reaction with the novel agent rovalpituzumab tesirine.
    Hou JL; Bridges AG
    Int J Dermatol; 2018 Mar; 57(3):e17-e19. PubMed ID: 29319846
    [No Abstract]   [Full Text] [Related]  

  • 31. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
    Liu Z; Li X; He X; Xu Y; Wang X
    BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic Hepatocellular Carcinoma Treated With Zoledronic Acid.
    Nguyen AL; Cao H; Thinn MM
    J Oncol Pract; 2018 Jan; 14(1):52-54. PubMed ID: 28945506
    [No Abstract]   [Full Text] [Related]  

  • 34. Ramucirumab treatment in hepatocellular carcinoma.
    Longo F; Carrato A
    Chin Clin Oncol; 2020 Dec; 9(6):83. PubMed ID: 32008334
    [No Abstract]   [Full Text] [Related]  

  • 35. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo A; Dadduzio V; Ricci AD; Massari F; Di Federico A; Gadaleta-Caldarola G; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):371-378. PubMed ID: 34167433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
    Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
    Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camrelizumab: an investigational agent for hepatocellular carcinoma.
    Xu B; Sun HC
    Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
    Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
    Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.